RT Journal Article
SR Electronic
T1 Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1629
OP 1634
DO 10.21873/anticanres.15638
VO 42
IS 3
A1 IKKO TOMISAKI
A1 MIRII HARADA
A1 AKINORI MINATO
A1 YUJIRO NAGATA
A1 RIEKO KIMURO
A1 KATSUYOSHI HIGASHIJIMA
A1 KENICHI HARADA
A1 NAOHIRO FUJIMOTO
YR 2022
UL http://ar.iiarjournals.org/content/42/3/1629.abstract
AB Background/Aim: This study aimed to clarify the impact of proton pump inhibitors (PPIs) on oncological outcomes in patients who received pembrolizumab for advanced urothelial carcinoma (UC). Patients and Methods: Forty advanced UC patients treated with pembrolizumab were retrospectively reviewed and divided into two groups (PPI: 15 patients; without PPI: 25 patients). Tumor response and survival were compared between these groups. The factors associated with survival were also investigated. Results: The objective response rate was significantly lower in the group with PPIs compared with the group without PPIs. Both progression-free survival (PFS) and overall survival (OS) were significantly shorter in the group with PPIs than in the group without PPIs. The use of PPIs was a significant predictor of poor PFS and OS in multivariate analysis. Conclusion: The use of PPIs was negatively associated with tumor response and survival in patients with advanced UC treated with pembrolizumab.